Vivani Medical, INC. (VANI) — SEC Filings

Overview

Vivani Medical, INC. (VANI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: Vivani Medical, Inc. filed an 8-K on March 26, 2026, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with specific details expected to be found within the attached documents.

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 2 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Vivani Medical, INC. is neutral.

Filing Type Overview

Vivani Medical, INC. (VANI) has filed 28 8-K, 3 10-K, 5 10-Q, 2 DEF 14A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• Vivani Medical Files 8-K on Financials — 8-K · Mar 26, 2026 Risk: medium
  Vivani Medical, Inc. filed an 8-K on March 26, 2026, reporting on its results of operations and financial condition. The filing includes financial statements an
• Vivani Shifts Focus to Obesity Implants, Reports Positive Preclinical Data — 10-K · Mar 26, 2026 Risk: high
  Vivani Medical, Inc. (VANI) is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting subdermal drug implant candidates u
• Vivani's Losses Widen Amid Increased R&D for GLP-1 Implants — 10-Q · Nov 13, 2025 Risk: high
  Vivani Medical, Inc. (VANI) reported a net loss of $6.53 million for the three months ended September 30, 2025, an increase from $6.04 million in the same perio
• Vivani Medical Files 8-K: Material Agreement, Equity Sales — 8-K · Oct 28, 2025 Risk: medium
  Vivani Medical, Inc. filed an 8-K on October 28, 2025, reporting on events that occurred on October 26, 2025. The filing indicates an entry into a material defi
• Vivani Medical Files 8-K — 8-K · Oct 3, 2025 Risk: low
  Vivani Medical, Inc. filed an 8-K on October 3, 2025, reporting on other events and financial statements. The company, formerly known as Second Sight Medical Pr
• Vivani Medical Files 8-K — 8-K · Sep 17, 2025 Risk: low
  Vivani Medical, Inc. filed an 8-K on September 17, 2025, reporting other events and financial statements. The company, formerly known as Second Sight Medical Pr
• Vivani Medical Files 8-K — 8-K · Sep 9, 2025 Risk: low
  Vivani Medical, Inc. filed an 8-K on September 9, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Vivani Medical Files 8-K — 8-K · Sep 4, 2025 Risk: low
  Vivani Medical, Inc. filed an 8-K on September 4, 2025, reporting other events and financial statements. The company, formerly known as Second Sight Medical Pro
• Vivani's Losses Widen Amid R&D Push; Cash Dwindles — 10-Q · Aug 13, 2025 Risk: high
  Vivani Medical, Inc. (VANI) reported a net loss of $7.144 million for the three months ended June 30, 2025, an increase from $5.356 million in the same period o
• Vivani Medical Files 8-K on Financials and Operations — 8-K · Aug 5, 2025 Risk: medium
  Vivani Medical, Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition. The filing also includes information on Reg
• Vivani Medical Reports Shareholder Vote Matter — 8-K · Jun 25, 2025 Risk: medium
  Vivani Medical, Inc. filed an 8-K on June 25, 2025, reporting on a matter submitted to a vote of its security holders on June 24, 2025. The filing does not disc
• Vivani Medical Files 8-K with Corporate Updates — 8-K · Jun 17, 2025 Risk: low
  Vivani Medical, Inc. filed an 8-K on June 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's
• Vivani Medical Announces Board and Executive Changes — 8-K · Jun 11, 2025 Risk: medium
  Vivani Medical, Inc. announced on June 11, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of
• Vivani Medical Files 8-K — 8-K · May 29, 2025 Risk: low
  Vivani Medical, Inc. filed an 8-K on May 29, 2025, reporting other events and financial statements. The company, formerly known as Second Sight Medical Products
• Vivani Medical Files 8-K with Key Business Updates — 8-K · May 13, 2025 Risk: medium
  Vivani Medical, Inc. filed an 8-K on May 12, 2025, reporting on several key events. These include entering into a material definitive agreement, updates on resu
• Vivani Medical Files DEF 14A for 2024 — DEF 14A · Apr 29, 2025 Risk: medium
  Vivani Medical, Inc. filed a DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corpor
• Vivani Medical Files 8-K — 8-K · Apr 15, 2025 Risk: low
  Vivani Medical, Inc. filed an 8-K on April 15, 2025, reporting an event that occurred on April 12, 2025. The filing primarily concerns financial statements and
• Vivani Medical Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Vivani Medical, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Second Sight M
• Vivani Medical Files 8-K on Key Agreements and Sales — 8-K · Mar 27, 2025 Risk: medium
  Vivani Medical, Inc. filed an 8-K on March 26, 2025, reporting on several key events. These include entering into a material definitive agreement, unregistered
• Vivani Medical Files 8-K — 8-K · Mar 26, 2025 Risk: low
  Vivani Medical, Inc. filed an 8-K on March 26, 2025, reporting other events and financial statements. The company, formerly known as Second Sight Medical Produc
• Vivani Medical Files 8-K on Financials and Operations — 8-K · Mar 13, 2025 Risk: medium
  Vivani Medical, Inc. filed an 8-K on March 13, 2025, reporting on its financial condition and other events. The filing includes information on results of operat
• Vivani Medical Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
  Vivani Medical, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Second Sight Medical Products Inc., is incorporated
• Vivani Medical Relocates, Former Name Revealed — 8-K · Oct 22, 2024 Risk: low
  Vivani Medical, Inc. filed an 8-K on October 22, 2024, to report other events and financial statements. The filing indicates a change in the company's principal
• Vivani Medical Files 8-K, Relocates Offices — 8-K · Sep 26, 2024 Risk: low
  Vivani Medical, Inc. filed an 8-K on September 26, 2024, to report other events and financial statements. The filing indicates a change in the company's princip
• Vivani Medical Files 8-K — 8-K · Sep 23, 2024 Risk: low
  Vivani Medical, Inc. filed an 8-K on September 23, 2024, reporting other events and financial statements. The company, formerly known as Second Sight Medical Pr
• Vivani Medical Files 8-K — 8-K · Sep 4, 2024 Risk: low
  Vivani Medical, Inc. filed an 8-K on September 4, 2024, reporting other events and financial statements. The company, formerly known as Second Sight Medical Pro
• Vivani Medical Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Vivani Medical, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations.
• Vivani Medical Files 8-K — 8-K · Jul 11, 2024 Risk: low
  Vivani Medical, Inc. filed an 8-K on July 11, 2024, reporting other events and financial statements. The company, formerly known as Second Sight Medical Product
• Vivani Medical Files 8-K on Shareholder Votes and Exhibits — 8-K · Jun 28, 2024 Risk: low
  Vivani Medical, Inc. filed an 8-K on June 28, 2024, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The filing a
• Vivani Medical Files 8-K — 8-K · Jun 13, 2024 Risk: low
  Vivani Medical, Inc. filed an 8-K on June 13, 2024, reporting other events and financial statements as of June 7, 2024. The filing details the company's operati
• Vivani Medical, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  Vivani Medical, Inc. (VANI) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Vivani Medical, Inc. filed a 10-Q report for the period ending March 3
• Vivani Medical, Inc. Files DEF 14A for Annual Meeting and Executive Compensation — DEF 14A · Apr 29, 2024 Risk: low
  Vivani Medical, Inc. (VANI) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Vivani Medical, Inc. filed a DEF 14A with the SEC on April 29, 202
• Vivani Medical Files 8-K with Material Agreement Details — 8-K · Apr 23, 2024 Risk: medium
  On April 22, 2024, Vivani Medical, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibit
• Vivani Medical, Inc. Files 2023 10-K Report — 10-K · Mar 26, 2024 Risk: medium
  Vivani Medical, Inc. (VANI) filed a Annual Report (10-K) with the SEC on March 26, 2024. Vivani Medical, Inc. filed its 10-K report for the fiscal year ending D
• Vivani Medical Appoints New CFO, Directors — 8-K · Mar 6, 2024 Risk: medium
  Vivani Medical, Inc. announced on March 4, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directo
• Vivani Medical Enters Material Definitive Agreement — 8-K · Mar 5, 2024 Risk: medium
  Vivani Medical, Inc. announced on March 1, 2024, that it entered into a Material Definitive Agreement. The company also filed financial statements and exhibits
• Vivani Medical Files 8-K for Regulation FD Disclosure — 8-K · Feb 28, 2024 Risk: low
  Vivani Medical, Inc. filed an 8-K on February 28, 2024, to disclose information under Regulation FD and to include financial statements and exhibits. The filing
• Vivani Medical Files 8-K, Confirms Nasdaq Listing — 8-K · Jan 10, 2024
  Vivani Medical, Inc. filed an 8-K on January 10, 2024, reporting an event that occurred on January 9, 2024. This filing is a standard 'Other Events' report, ind

Risk Profile

Risk Assessment: Of VANI's 37 recent filings, 3 were flagged as high-risk, 16 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Vivani Medical, INC.'s most recent 10-K filing (Mar 26, 2026):

• Revenue: $0
• Net Income: N/A
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: N/A
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Adam Mendelsohn
• Scott Dunbar
• Dr. David R. Chen
• Mr. David L. Johnson
• Mr. Michael L. Ringer

Industry Context

Vivani operates in the highly competitive biopharmaceutical sector, specifically focusing on drug delivery technologies for chronic diseases like obesity. The industry is characterized by significant R&D investment, lengthy development cycles, and stringent regulatory oversight. Key trends include the growing demand for effective obesity treatments, exemplified by the success of GLP-1 agonists, and innovation in drug delivery systems to improve patient adherence and outcomes.

Top Tags

8-K (7) · financials (7) · filing (7) · 8-k (5) · material-agreement (4) · regulation-fd (4) · corporate-filing (4) · disclosure (4) · corporate-governance (4) · corporate-update (4)

Key Numbers

• aggregate market value of non-affiliate common stock: $45.9 million — as of June 30, 2025, indicating market capitalization
• shares of common stock outstanding: 84,647,803 — as of March 25, 2026
• approximate patient medication non-adherence rate: 50% — problem Vivani's technology aims to solve
• weight loss in preclinical NPM-139 rat study: 20% — maintained for a full year after single administration
• sham-implant adjusted liver fat reduction with NPM-115: 82% — at Week 12 in an obese mouse model from a single administration
• target duration of drug delivery for NPM-139 and NPM-133: 6 months — potential for once or twice yearly administration
• Cash and cash equivalents: $2.63M — Decreased from $18.35M at Dec 31, 2024, indicating significant cash burn.
• Net loss for nine months: $19.98M — Widened from $17.44M in the prior year, reflecting increased operating expenses.
• Research and development expenses: $13.50M — Increased from $11.44M for the nine months, driven by clinical trial advancements.
• Weight loss in preclinical study: 20% — Achieved by NPM-139 (semaglutide implant) in rats, maintained for over seven months.
• Common shares outstanding: 72,952,235 — As of November 12, 2025.
• Total Stockholders' Equity: $1.31M — Significantly reduced from $17.61M at December 31, 2024, highlighting financial strain.
• SEC File Number: 001-36747 — Identifies the company's filing with the SEC
• IRS Employer Identification No.: 02-0692322 — Company's tax identification number
• Net loss for Q2 2025: $7.144M — Increased from $5.356M in Q2 2024

Related Companies

NVO · LLY · VVNI

Frequently Asked Questions